Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
N/A
1(33.3%)
3Total
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02983487Completed

Pertussis Immunization Programs in Low Income Countries

Role: collaborator

NCT04015713Unknown

Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset

Role: collaborator

NCT04089436Unknown

SouthEast Asia Encephalitis Project

Role: collaborator

NCT01331811Not ApplicableCompleted

Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)

Role: collaborator

NCT02118090Phase 4Completed

Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:

Role: lead

NCT01379326Phase 4Completed

Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2

Role: collaborator

All 6 trials loaded